DOCSLIB.ORG

Fine Test Your Good Research Partner

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Fine Test Your Good Research Partner Fine Test your good research partner Wuhan Fine Biotech Co.,Ltd. EH4223 Human 25(OH) Vitamin D ELISA Kit EH1208 Human A1BG(Alpha-1B-glycoprotein) ELISA Kit EH2076 Human 26S-PSM ELISA Kit EH4021 Human AA(Arachidonic Acid) ELISA Kit Add: B9 Bld, High-tech Medical Devices Park, EH4025 Human 27 OHC(2A7-Hydroxycholesterol) ELISA Kit EH1172 Human ABCB5 ELISA Kit No. 818 Gaoxin Ave. East Lake High-tech Development Zone, EH4250 Human 3MH(3-methylhistidine) ELISA Kit EH0994 Human ABP1 ELISA Kit Wuhan, China(430206) EH2080 Human 4-HNE(4-Hydroxynonenal) ELISA Kit EH4241 Human Acetylated HB ELISA Kit Tel:0086(027)87384275 EH2110 Human 5-HETE ELISA Kit EH4216 Human Acetylated p53 ELISA Kit Fax:0086(027)87800889 EH4230 Human 5-Me-THF ELISA Kit EH0483 Human ACHAP ELISA Kit E-mail:fi[email protected] EH4170 Human 5-MTHF ELISA Kit EH1362 Human Acetylcholinesterase ELISA Kit Website:www.fn-test.com ISO9001:2008 EH1049 Human 8ISOPG(8-iso-Prostaglandin F2α) ELISA Kit EH4020 Human AchR-Ab ELISA Kit www.fn-test.com EH1580 Human ACLY(ATP-citrate synthase) ELISA Kit EH2684 Human Aβ40(Amyloid Beta 40) ELISA Kit EH3074 Human Flt3L ELISA Kit EH0938 Human HBA1(Hemoglobin subunit alpha) ELISA Kit EH0600 Human ACO1(Aconitase 1) ELISA Kit EH2685 Human Aβ42(Amyloid Beta 42) ELISA Kit EH0729 Human FLT4 ELISA Kit EH0457 Human HbA1c(Glycosylated hemoglobin A1c) ELISA Kit EH0606 Human A-CoA(Acetyl Coenzyme A) ELISA Kit EH0424 Human B2M(Beta2-microglobulin) ELISA Kit EH1680 Human FMOD(Fibromodulin) ELISA Kit EH3211 Human Hemoglobin C ELISA Kit EH4018 Human ACP(Acid phosphatase) ELISA Kit EH1146 Human BECN1(Beclin-1) ELISA Kit EH0384 Human FPA(Fibrinopeptide A) ELISA Kit EH4107 Human hepatitis B virus Core antibody ELISA Kit EH0427 Human ACP3/PAP ELISA Kit EH4169 Human beta glucan(beta glucan) ELISA Kit EH3081 Human FPB(Fibrinopeptide B) ELISA Kit EH3212 Human Carboxyhemoglobin ELISA Kit EH1081 Human ACP5 ELISA Kit EH2740 Human C4(Complement Component 4) ELISA Kit EH1997 Human FPR2 ELISA Kit EH4106 Human hepatitis B virus E Antibody ELISA Kit EH1509 Human ACTA2(Actin, aortic smooth muscle) ELISA Kit EH0680 Human C5(Complement C5) ELISA Kit EH3082 Human fPSA ELISA Kit EH4105 Human hepatitis B virus E Antigen ELISA Kit EH0917 Human ACTG1(Actin Gamma 1) ELISA Kit EH0656 Human C7 ELISA Kit EH0141 Human Fractalkine ELISA Kit EH4104 Human hepatitis B virus surface antibody ELISA Kit EH1777 Human ACTN2(Actinin Alpha 2) ELISA Kit EH0681 Human C8A ELISA Kit EH3084 Human FRS2 ELISA Kit EH4002 Human hepatitis B virus Surface Antigen ELISA Kit EH1251 Human ACTN3(Alpha-actinin-3) ELISA Kit EH0673 Human C9(Complement component C9) ELISA Kit EH1915 Human FSCN1(Fascin) ELISA Kit EH4108 Human hepatitis C virus-Immunoglobulin M ELISA Kit EH1627 Human ACTN4(Alpha-actinin-4) ELISA Kit EH4140 Human calprotectin ELISA Kit EH0845 Human FSCN2(Fascin-2) ELISA Kit EH4011 Human HCY(Homocysteine) ELISA Kit EH2585 Human ACVB(Activin B) ELISA Kit EH1659 Human CALR(Calreticulin) ELISA Kit EH0393 Human FSH ELISA Kit EH3219 Human HDAC2(Histone Deacetylase 2) ELISA Kit EH4262 Human Acyl-CoA desaturase ELISA Kit EH1966 Human CALU(Calumenin) ELISA Kit EH3088 Human FSHR ELISA Kit EH4903 Human HDAC6(Histone deacetylase 6) ELISA Kit EH1544 Human ADA(Adenosine deaminase) ELISA Kit EH2933 Human DAG1 ELISA Kit EH3089 Human FSP ELISA Kit EH4399 Human Hepatitis D Virus -Immunoglobulin M ELISA Kit EH2374 Human ADAL ELISA Kit EH1546 Human DAO(D-amino-acid oxidase) ELISA Kit EH0533 Human FST ELISA Kit EH3222 Human Hepc25(Hepcidin 25) ELISA Kit EH0622 Human AGE ELISA Kit EH4165 Human DAO(Diamine Oxidase) ELISA Kit EH0747 Human GAA(Lysosomal alpha-glucosidase) ELISA Kit EH1020 Human HPSE(Heparanase) ELISA Kit EH4231 Human ALAD ELISA Kit EH2934 Human DAP6(Death Associated Protein 6) ELISA Kit EH3098 Human GABA ELISA Kit EH0166 Human IGF-2 ELISA Kit EH2093 Human ALAD ELISA Kit EH2935 Human DAT(Dopamine Transporter) ELISA Kit EH4183 Human GABP1 ELISA Kit EH3257 Human IGF2BP3 ELISA Kit EH4019 Human ALP(Alkanine Phosphatase) ELISA Kit EH1590 Human DBH(Dopamine beta-hydroxylase) ELISA Kit EH4182 Human GABPA ELISA Kit EH4189 Human ILK-1(Integrin-Linked Kinase 1) ELISA Kit EH4144 Human alpha 1 microglobulin ELISA Kit EH2936 Human DBP/DNA Binding Protein ELISA Kit EH1433 Human GAD1 ELISA Kit EH4177 Human LIPE(Hormone-sensitive lipase) ELISA Kit EH4232 Human Alpha Tocopherol ELISA Kit EH2937 Human DBP(Vitamin D Binding Protein) ELISA Kit EH0732 Human GAD2 ELISA Kit EH0776 Human LIPF(Gastric triacylglycerol lipase) ELISA Kit EH0788 Human ALPL ELISA Kit EH0837 Human DEFB4A ELISA Kit EH3100 Human GAD-Ab ELISA Kit EH3297 Human LIPH(Lipase H) ELISA Kit EH1391 Human ALPP ELISA Kit EH4265 Human DEGS2(delta-4-desaturase) ELISA Kit EH3101 Human GADL1 ELISA Kit EH0012 Human Lipocalin-2 ELISA Kit EH2620 Human AMA IgA(Anti-Myelin antibody IgA) ELISA Kit EH2958 Human DPYD ELISA Kit EH4235 Human GAGs(Glycosaminoglycan) ELISA Kit EH1452 Human MCP/CD46 ELISA Kit EH1108 Human AMACR(Alpha-methylacyl-CoA racemase) ELISA Kit EH2961 Human DR-70TM ELISA Kit EH1219 Human GAL(Galanin peptides) ELISA Kit EH1672 Human OTC ELISA Kit EH0567 Human AMBP(Protein AMBP ) ELISA Kit EH1473 Human DRD1(D(1A) dopamine receptor) ELISA Kit EH3103 Human GAL12(Galectin 12 ) ELISA Kit EH3485 Human OVA sIgE(Ovalbumin Specific IgE) ELISA Kit EH0924 Human AMD1 ELISA Kit EH2962 Human DS(Dermatan Sulfate) ELISA Kit EH3104 Human GAL14(Galectin 14 ) ELISA Kit EH3486 Human OVA sIgG(Ovalbumin Specific IgG) ELISA Kit EH1575 Human AMELX(Amelogenin, X isoform) ELISA Kit EH1846 Human DSCR6(Protein ripply3) ELISA Kit EH3110 Human GAL8(Galectin 8) ELISA Kit EH3548 Human pERK ELISA Kit EH1690 Human AMFR(E3 ubiquitin-protein ligase AMFR) ELISA Kit EH2963 Human DSE(Dermatan Sulfate Epimerase) ELISA Kit EH4013 Human Galactose-Deficient IgA1 ELISA Kit EH3549 Human PEX2(Peroxisomal Biogenesis Factor 2) ELISA Kit EH0528 Human AMH(Muellerian-inhibiting factor ) ELISA Kit EH1026 Human DSG1(Desmoglein-1) ELISA Kit EH1710 Human GALC(Galactocerebrosidase) ELISA Kit EH3550 Human PF3(Platelet Factor 3) ELISA Kit EH2205 Human AMOT(Angiomotin) ELISA Kit EH4022 Human EDHF ELISA Kit EH0768 Human GALNS ELISA Kit EH4233 Human PGE2(Prostaglandin E2) ELISA Kit EH2206 Human AMOTL1(Angiomotin-like protein 1) ELISA Kit EH0693 Human FGG(Fibrinogen gamma chain) ELISA Kit EH1497 Human GAP43(Neuromodulin) ELISA Kit EH3562 Human PGF2α(Prostaglandin F2α) ELISA Kit EH2621 Human AMPH(anti amphiphysin) ELISA Kit EH3063 Human FGL1(Fibrinogen Like Protein 1) ELISA Kit EH0997 Human GCK(Glucokinase) ELISA Kit EH1428 Human PGK1(Phosphoglycerate kinase 1) ELISA Kit EH3774 Human Anti HCV(Hepatitis C Virus Antibody) ELISA Kit EH3064 Human FGL2(Fibrinogen Like Protein 2) ELISA Kit EH1565 Human GCLC ELISA Kit EH1717 Human PGLYRP2 ELISA Kit EH2640 Human Anti-Acetylcholine Receptor Antibody ELISA Kit EH3065 Human FGα(Fibrinogen Alpha) ELISA Kit EH3122 Human GCLM ELISA Kit EH3564 Human P-GP(Permeability Glycoprotein) ELISA Kit EH4171 Human Anti-DSG3 antibody ELISA Kit EH3066 Human FGβ(Fibrinogen Beta) ELISA Kit EH2295 Human GDF1 ELISA Kit EH4132 Human PHF6(PHD finger protein 6) ELISA Kit EH1623 Human Anti-Ganglioside M1 Antibody ELISA Kit EH0423 Human FITC/ANXA5(Annexin A5) ELISA Kit EH1312 Human GDF10 ELISA Kit EH4132 Human PHF6(PHD finger protein 6) ELISA Kit EH2645 Human Anti-Myeloperoxidase Antibody ELISA Kit EH1097 Human FKBP5 ELISA Kit EH0908 Human GHRH(Somatoliberin) ELISA Kit EH4215 Human Phospho ser15 P53 ELISA Kit EH4161 Human anti-nuclear antibody ELISA Kit EH1273 Human FKBP8 ELISA Kit EH0355 Human GHRL(Ghrelin) ELISA Kit EH2144 Human PIINP ELISA Kit EH4162 Human anti-ox-LDL antibody ELISA Kit EH1353 Human FLG(Filaggrin) ELISA Kit EH1932 Human GLT25D1 ELISA Kit EH3582 Human PK2(Prokineticin 2) ELISA Kit EH2646 Human Anti-Surv(Anti-Survivin Antibody) ELISA Kit EH1297 Human FLNB(Filamin-B) ELISA Kit EH2159 Human GP6(Platelet glycoprotein VI) ELISA Kit EH3585 Human PKC(Protein Kinase C) ELISA Kit EH4160 Human anti-thrombin III antibody ELISA Kit EH1298 Human FLNC(Filamin-C) ELISA Kit EH3162 Human GP-73(Golgi Protein 73) ELISA Kit EH3600 Human PKR2(Prokineticin Receptor 2) ELISA Kit EH4180 Human Anti-tissue transglutaminase IgG ELISA Kit EH3070 Human FLNα(Filamin A, Alpha) ELISA Kit EH0826 Human GPX1 ELISA Kit EH3601 Human PL(Placental Lactogen) ELISA Kit EH4138 Human AP12(Apelin 12) ELISA Kit EH3071 Human FLNβ(Filamin B, Beta) ELISA Kit EH1596 Human GPX2 ELISA Kit EH4014 Human Reg3b ELISA Kit EH4259 Human a-SNCO ELISA Kit EH1351 Human FLOT1(Flotillin-1) ELISA Kit EH2531 Human GPX3 ELISA Kit EH1271 Human REG3α ELISA Kit EH1174 Human ASPN(Asporin) ELISA Kit EH3072 Human FLOT2(Flotillin 2) ELISA Kit EH3170 Human GR ELISA Kit EH0847 Human REG3γ ELISA Kit EH4176 Human Asprosin ELISA Kit EH0504 Human FLT3 ELISA Kit EH4109 Human HAV-IgM ELISA Kit EH0267 Human REG-4 ELISA Kit About Us Fine Biotech is an ISO9001:2008 Certified manufactory, offering over 20,000 high quality reagents and kits include primary antibodies, ELISA Kits, recombinant proteins which are widely applied to life science research. Fine biotech technical support are dedicated to providing with professional and friendly assistance to scientists and researchers. Strict and multiple quality control ensure that our products continue to successfully supply for the international market. Moreover, we strive to continuously improve the customer experience through comprehensive technical support. High quality, rapid turnaround and personal support for all FineTest services are guaranteed. ELISA Kits Highlights Good quality control for every kit by every lot. Included intra and inter-assay precision, sensitivity, recovery, stability, specificity. Unique SABC amplification system improve FineTest kits detection sensitivity and specificity. Easy and safe shipping. FineTest kits stored at 4℃ are very suitable for the long international transportation. Offered thousands of kits allow specific, quantitative measurements of disease-related proteins, including apoptosis, cancer, immunology, neuroscience, cytokines, infectious, metabolism.
Load more

Recommended publications
  • Neuroinflammation Triggered by Β-Glucan/Dectin-1 Signaling Enables CNS Axon Regeneration
    Neuroinflammation triggered by β-glucan/dectin-1 signaling enables CNS axon regeneration Katherine T. Baldwina,b,1, Kevin S. Carbajalc,d,1, Benjamin M. Segalc,d,2, and Roman J. Gigera,b,c,d,2 aDepartment of Cell and Developmental Biology, bCellular and Molecular Biology Graduate Program, cNeuroscience Graduate Program, and dHoltom-Garrett Program in Neuroimmunology, Department of Neurology, University of Michigan School of Medicine, Ann Arbor, MI 48109 Edited by Ben A. Barres, Stanford University School of Medicine, Stanford, CA, and approved January 22, 2015 (received for review December 22, 2014) Innate immunity can facilitate nervous system regeneration, yet growth can be undermined by concurrent toxicity (9). A deeper the underlying cellular and molecular mechanisms are not well understanding of these opposing effects will be important for understood. Here we show that intraocular injection of lipopoly- exploiting immunomodulatory pathways to promote neural re- saccharide (LPS), a bacterial cell wall component, or the fungal cell pair while minimizing bystander damage. wall extract zymosan both lead to rapid and comparable intravi- In the present study, we investigated the pathways that drive treal accumulation of blood-derived myeloid cells. However, when innate immune-mediated axon regeneration after ONC. We in- combined with retro-orbital optic nerve crush injury, lengthy duced sterile inflammation in the vitreous on the day of injury by growth of severed retinal ganglion cell (RGC) axons occurs only i.o. administration of zymosan or constituents of zymosan clas- in zymosan-injected mice, and not in LPS-injected mice. In mice sified as pathogen-associated molecular patterns (PAMPs). PAMPs dectin-1 deficient for the pattern recognition receptor but not are highly conserved microbial structures that serve as ligands for TLR2 , Toll-like receptor-2 ( ) zymosan-mediated RGC regeneration pattern recognition receptors (PRRs).
    [Show full text]
  • 03 November 2019 Palm Wings Ephesus Hotel Congress Center, Kus¸Adası, Aydın (Turkey)
    www.actaphysiol.org December 2019 • Volume 227 • Supplement 722 OFFICIAL JOURNAL OF THE FEDERATION OF EUROPEAN PHYSIOLOGICAL SOCIETIES Turkish Society of Physiological Sciences 45th National Physiology Congress 31 October – 03 November 2019 Palm Wings Ephesus Hotel Congress Center, Kus¸adası, Aydın (Turkey) PUBLICATION HISTORY Acta Physiologica 2006– Acta Physiologica Scandinavica 1940–2005 Skandinavisches Archiv für Physiologie 1889–1939 AAPHA_v227_is722_issue-info.inddPHA_v227_is722_issue-info.indd 1 229-Nov-199-Nov-19 12:00:2112:00:21 PMPM Chief Editor INFORMATION FOR SUBSCRIBERS Pontus B. Persson, Berlin Acta Physiologica is published in 12 issues per year. Subscription prices for 2020 € Editors are: Institutional: 1112 (Europe), $1662 (The Americas), $1942 (Rest of World). Cardiovascular Physiology – Frantisek Kolar, Prague; Holger Nilsson, Gothenburg Prices are exclusive of tax. Australian GST, Canadian GST/HST and European and William E. Louch, Oslo VAT will be applied at the appropriate rates. For more information on current tax Cell Biology – Sari Lauri, Helsinki rates, please go to www.wileyonlinelibrary.com/tax-vat. The price includes online Chronobiology and Endocrinology – Charna Dibner, Geneva access to the current and all online back fi les to January 1st 2016, where available. Exercise Physiology – Jan Henriksson, Stockholm For other pricing options, including access information and terms and conditions, Gastrointestinal Physiology – Markus Sjöblom, Uppsala please visit www.wileyonlinelibrary.com/access Infl ammation – Joakim Ek, Gothenburg Metabolism and Nutritional Physiology – Karl-Heinz Herzig, Oulu DELIVERY TERMS AND LEGAL TITLE Muscle Physiology – Gabriele Pfi tzer, Cologne Where the subscription price includes print issues and delivery is to the recipients Nervous System – Alexej Verkhratsky, Manchester address, delivery terms are Delivered at Place (DAP); the recipient is responsible Renal Physiology – Peter Bie, Odense; Boye L.
    [Show full text]
  • W W W .Bio Visio N .Co M New Products Added in 2020
    New products added in 2020 Please find below a list of all the products added to our portfolio in the year 2020. Assay Kits Product Name Cat. No. Size Product Name Cat. No. Size N-Acetylcysteine Assay Kit (F) K2044 100 assays Human GAPDH Activity Assay Kit II K2047 100 assays Adeno-Associated Virus qPCR Quantification Kit K1473 100 Rxns Human GAPDH Inhibitor Screening Kit (C) K2043 100 assays 20 Preps, Adenovirus Purification Kit K1459 Hydroxyurea Colorimetric Assay Kit K2046 100 assays 100 Preps Iodide Colorimetric Assay Kit K2037 100 assays Aldehyde Dehydrogenase 2 Inhibitor Screening Kit (F) K2011 100 assays Laccase Activity Assay Kit (C) K2038 100 assays Aldehyde Dehydrogenase 3A1 Inhibitor Screening Kit (F) K2060 100 assays 20 Preps, Lentivirus and Retrovirus Purification Kit K1458 Alkaline Phosphatase Staining Kit K2035 50 assays 100 Preps Alpha-Mannosidase Activity Assay Kit (F) K2041 100 assays Instant Lentivirus Detection Card K1470 10 tests, 20 tests Beta-Mannosidase Activity Assay Kit (F) K2045 100 assays Lentivirus qPCR Quantification Kit K1471 100 Rxns 50 Preps, Buccal Swab DNA Purification Kit K1466 Maleimide Activated KLH-Peptide Conjugation Kit K2039 5 columns 250 Preps Methionine Adenosyltransferase Activity Assay Kit (C) K2033 100 assays CD38 Activity Assay Kit (F) K2042 100 assays miRNA Extraction Kit K1456 50 Preps EZCell™ CFDA SE Cell Tracer Kit K2057 200 assays MMP-13 Inhibitor Screening Kit (F) K2067 100 assays Choline Oxidase Activity Assay Kit (F) K2052 100 assays Mycoplasma PCR Detection Kit K1476 100 Rxns Coronavirus
    [Show full text]
  • Follicle-Stimulating Hormone (FSH)
    Hormone Structure (1) Principal Source Link to diagram showing locations of the main endocrine glands Thyroid-stimulating hormone (TSH) protein (201) Follicle-stimulating hormone (FSH) protein (204) Luteinizing hormone (LH) protein (204) Anterior lobe of pituitary Prolactin (PRL) protein (198) Growth hormone (GH) protein (191) Adrenocorticotropic hormone (ACTH) peptide (39) Vasopressin peptide (9) Posterior lobe of pituitary Oxytocin peptide (9) Thyrotropin-releasing hormone (TRH) peptide (3) Gonadotropin-releasing hormone (GnRH) peptide (10) Growth hormone-releasing hormone (GHRH) peptides (40, 44) Hypothalamus Corticotropin-releasing hormone (CRH) peptide (41) Somatostatin peptides (14, 28) Dopamine tyrosine derivative Melatonin tryptophan derivative Pineal gland Thyroxine (T4) tyrosine derivative Thyroid Gland Calcitonin peptide (32) Parathyroid hormone (PTH) protein (84) Parathyroid glands FGF-23 (phosphatonin) protein (251) Osteocalcin peptide (49) Bone Lipocalin 2 protein (198) Erythropoietin (EPO) protein (166) Glucocorticoids (e.g., cortisol) steroids Mineralocorticoids (e.g., aldosterone) steroids Adrenal cortex Androgens (e.g., testosterone) steroids Adrenaline (epinephrine) tyrosine derivative Adrenal medulla Noradrenaline (norepinephrine) tyrosine derivative Estrogens (e.g., estradiol) steroid Ovarian follicle Progesterone steroid Corpus luteum and placenta Human chorionic gonadotropin (HCG) protein (237) Trophoblast and placenta Androgens (e.g., testosterone) steroid Testes Insulin protein (51) Glucagon peptide (29) Pancreas
    [Show full text]
  • US 2017/0020926 A1 Mata-Fink Et Al
    US 20170020926A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0020926 A1 Mata-Fink et al. (43) Pub. Date: Jan. 26, 2017 (54) METHODS AND COMPOSITIONS FOR 62/006,825, filed on Jun. 2, 2014, provisional appli MMUNOMODULATION cation No. 62/006,829, filed on Jun. 2, 2014, provi sional application No. 62/006,832, filed on Jun. 2, (71) Applicant: RUBIUS THERAPEUTICS, INC., 2014, provisional application No. 61/991.319, filed Cambridge, MA (US) on May 9, 2014, provisional application No. 61/973, 764, filed on Apr. 1, 2014, provisional application No. (72) Inventors: Jordi Mata-Fink, Somerville, MA 61/973,763, filed on Apr. 1, 2014. (US); John Round, Cambridge, MA (US); Noubar B. Afeyan, Lexington, (30) Foreign Application Priority Data MA (US); Avak Kahvejian, Arlington, MA (US) Nov. 12, 2014 (US) ................. PCT/US2O14/0653O4 (21) Appl. No.: 15/301,046 Publication Classification (22) PCT Fed: Mar. 13, 2015 (51) Int. Cl. A6II 35/28 (2006.01) (86) PCT No.: PCT/US2O15/02O614 CI2N 5/078 (2006.01) (52) U.S. Cl. S 371 (c)(1), CPC ............. A61K 35/28 (2013.01); C12N5/0641 (2) Date: Sep. 30, 2016 (2013.01): CI2N 5/0644 (2013.01); A61 K Related U.S. Application Data 2035/122 (2013.01) (60) Provisional application No. 62/059,100, filed on Oct. (57) ABSTRACT 2, 2014, provisional application No. 62/025,367, filed on Jul. 16, 2014, provisional application No. 62/006, Provided are cells containing exogenous antigen and uses 828, filed on Jun. 2, 2014, provisional application No.
    [Show full text]
  • The Impaired Response of Circulating Asprosin Concentrations to Glucose Levels Fluctuation May Be One of the Causes of Type 2 Diabetes – a Narrative Review
    Trojanowska Paulina, Trojanowska Alina, Szydełko Joanna, Tywanek Ewa, Łuczyk Robert Jan. The impaired response of circulating asprosin concentrations to glucose levels fluctuation may be one of the causes of type 2 diabetes – a narrative review. Journal of Education, Health and Sport. 2020;10(9):846-854. eISSN 2391-8306. DOI http://dx.doi.org/10.12775/JEHS.2020.10.09.10 2 https://apcz.umk.pl/czasopisma/index.php/JEHS/article/view/JEHS.2020.10.09. 10 2 https://zenodo.org/record/4054287 The journal has had 5 points in Ministry of Science and Higher Education parametric evaluation. § 8. 2) and § 12. 1. 2) 22.02.2019. © The Authors 2020; This article is published with open access at Licensee Open Journal Systems of Nicolaus Copernicus University in Torun, Poland Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author (s) and source are credited. This is an open access article licensed under the terms of the Creative Commons Attribution Non commercial license Share alike. (http://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited. The authors declare that there is no conflict of interests regarding the publication of this paper. Received: 21.09.2020. Revised: 27.09.2020. Accepted: 28.09.2020. The impaired response of circulating asprosin concentrations
    [Show full text]
  • Oncomodulin and Macrophages Derived Factors in Pancreas Injury and Development Paradigms
    Vol.2, No.1, 1-8 (2013) Modern Research in Inflammation http://dx.doi.org/10.4236/mri.2013.21001 Oncomodulin and macrophages derived factors in pancreas injury and development paradigms Joël Fleury Djoba Siawaya1,2*, Carmen Capito1, Raphael Scharfmann1 1Centre de Recherche “Croissance et Signalisation”, Inserm Unité-845, Faculté de Médecine Paris 5, Paris, France; *Corresponding Author: [email protected], [email protected] 2Laboratoire National de Santé Publique, Unité de Recherche, Libreville, Gabon Received 6 December 2012; revised 14 January 2013; accepted 5 February 2013 ABSTRACT against beta cells appears to be the main cause for the loss of the insulin-producing beta cells leading to insulin Prior studies in the optic nerve injury paradigm deficiency whereas, in type 2 diabetes obesity related showed conflicting data regarding production pro-inflammatory response is involved in the develop- and significance of the Ca2+-binding protein on- ment of insulin resistance. comodulin (OCM). Some have shown its potent Although treatment options for the type 1 diabetes re- axon-regenerative or-growth attribute, where other main principally limited to insulin replacement therapy, showed little to no effect. We show here that today new avenues such as islet cell regeneration, re- pancreas inflammation lead to macrophages in- growth of host own islet cells or islet transplantation are filtration that produce OCM and inflamed tissues being explored. The principal roadblock to the wide- that express OCM receptors in vivo. In culture spread application of these new therapeutic approaches OCM has a cytostatic effect on embryonic pan- creas explants. Secretory products of zymosan- are the molecular mechanisms and relevant growth fac- activated macrophages are cytotoxic and fac- tors implicated in endocrine pancreas development which tors derived from non-activated macrophages are yet to be fully elucidated and which are required seem to promote pancreas development.
    [Show full text]
  • Asprosin-Neutralizing Antibodies As a Treatment for Metabolic Syndrome
    RESEARCH ARTICLE Asprosin-neutralizing antibodies as a treatment for metabolic syndrome Ila Mishra1†, Clemens Duerrschmid1†, Zhiqiang Ku2, Yang He3, Wei Xie1, Elizabeth Sabath Silva1, Jennifer Hoffman1, Wei Xin4, Ningyan Zhang2, Yong Xu3, Zhiqiang An2, Atul R Chopra1,5,6* 1Harrington Discovery Institute, University Hospitals, Cleveland, United States; 2Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, United States; 3Baylor College of Medicine, Houston, United States; 4Department of Pathology, Case Western Reserve University, Cleveland, United States; 5Department of Medicine, Case Western Reserve University, Cleveland, United States; 6Department of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, United States Abstract Background: Recently, we discovered a new glucogenic and centrally acting orexigenic hormone – asprosin. Asprosin is elevated in metabolic syndrome (MS) patients, and its genetic loss results in reduced appetite, leanness, and blood glucose burden, leading to protection from MS. Methods: We generated three independent monoclonal antibodies (mAbs) that recognize unique asprosin epitopes and investigated their preclinical efficacy and tolerability in the treatment of MS. Results: Anti-asprosin mAbs from three distinct species lowered appetite and body weight, and reduced blood glucose in a dose-dependent and epitope-agnostic fashion in three independent MS mouse models, with an IC50 of ~1.5 mg/kg. The mAbs displayed a half-life of over 3days in vivo, *For correspondence: with equilibrium dissociation-constants in picomolar to low nanomolar range. [email protected] Conclusions: We demonstrate that anti-asprosin mAbs are dual-effect pharmacologic therapy that †These authors contributed targets two key pillars of MS – over-nutrition and hyperglycemia.
    [Show full text]
  • Effect of Swimming Training on Levels of Asprosin, Lipid Profile, Glucose and Insulin Resistance in Rats with Metabolic Syndrome
    Obesity Medicine 15 (2019) 100111 Contents lists available at ScienceDirect Obesity Medicine journal homepage: www.elsevier.com/locate/obmed Original research Effect of swimming training on levels of asprosin, lipid profile, glucose and insulin resistance in rats with metabolic syndrome T ∗ Hossein Nakhaeia, Mehdi Mogharnasia, Hamed Fanaeib,c, a Department of Sport Sciences, Faculty of Sport Sciences, University of Birjand, Birjand, Iran b Pregnancy Health Research Center, Zahedan University of Medical Sciences, Zahedan, Iran c Department of Physiology, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran ARTICLE INFO ABSTRACT Keywords: Background: Asprosin is a novel biomarker that associated with type 2 diabetes mellitus. The aim of this study Continuous training was to investigate the effects of continuous and interval swimming training on the asprosin, lipid profile, glucose Interval training concentration and insulin resistance serum levels of rats with metabolic syndrome. Asprosin Methods: Forty-eight male Wistar rats were randomly divided into two groups, standard diet (SD) and high-fat Lipid profile diet (HD), and received their respective diets for a period of 12 weeks without exercise stimuli. After this period, Metabolic syndrome the animals were randomly divided into four groups (n = 8); normal control standard diet (NC), control (Ctr), continuous training (load 0–3% body mass, 5 d/wk, for 8 weeks, CT) and interval training (load 5–16% body mass, 5 d/wk, for 8 weeks, IT). The continuous and interval training consisted of a swimming exercise performed over eight weeks. Result: The NC and trained groups showed lower values of total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL-C) and glucose concentration compared to Ctr group.
    [Show full text]
  • Serum Concentration of Asprosin in New-Onset Type 2 Diabetes
    Naiemian et al. Diabetol Metab Syndr (2020) 12:65 https://doi.org/10.1186/s13098-020-00564-w Diabetology & Metabolic Syndrome RESEARCH Open Access Serum concentration of asprosin in new-onset type 2 diabetes Shakiba Naiemian1, Mohsen Naeemipour2, Mehdi Zarei3, Moslem Lari Najaf4, Ali Gohari2, Mohammad Reza Behroozikhah2, Hafez Heydari2* and Mohammad Miri5* Abstract Background: Asprosin, a newly identifed adipokine, is pathologically increased in individuals with insulin resist- ance. However, the available evidence on the association of asprosin and type 2 diabetes mellitus (T2DM) status is still scarce. Therefore, this study aimed to determine the relationship between serum concentrations of asprosin and T2DM status. Methods: This observational study was performed based on 194 adults (97 newly diagnosed T2DM and 97 healthy individuals). Anthropometric and biochemical variables were determined in all participants. Serum concentrations of asprosin were measured using enzyme-linked immunosorbent assay (ELISA). Results: In patients with T2DM, the serum concentrations of asprosin were signifcantly higher than the healthy con- trols (4.18 [IQR: 4.4] vs. 3.5 [IQR: 1.85], P < 0.001). The concentrations of asprosin were signifcantly correlated with body mass index (BMI) and fasting blood glucose (FBG) in healthy subjects and with BMI, FBG, hemoglobin A1c (HbA1c), homeostatic model assessment of insulin resistance (HOMA-IR), and quantitative insulin check index (QUICKI), triacyl- glycerol (TAG) and total cholesterol/high-density lipoprotein cholesterol (TC/HDL-C) ratio in the T2DM group. In fully adjusted model, the odds ratio (OR) of T2DM with serum concentrations of asprosin was approximately 1.547 (95% CI 1.293–1.850, P < 0.001) compared to the control group.
    [Show full text]
  • An Investigation of the Relationship Between New Fasting Hormone Asprosin, Obesity and Acute–Chronic Exercise: Current Systematic Review
    ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY https://doi.org/10.1080/13813455.2020.1767652 REVIEW ARTICLE An investigation of the relationship between new fasting hormone asprosin, obesity and acute–chronic exercise: current systematic review Halil _Ibrahim Ceylana and Ozcan€ Saygınb aFaculty of Kazim Karabekir Education, Physical Education and Sports Teaching Department, Ataturk University, Erzurum, Turkey; bFaculty of Sports Sciences, Coaching Science Department, Mugla Sitki Kocman University, Mugla, Turkey ABSTRACT ARTICLE HISTORY The purpose of this study was to reveal the relationship between new fasting hormone asprosin, obes- Received 31 March 2020 ity, and acute–chronic exercise. The prisma guidelines were followed in forming the methodological Revised 5 May 2020 model of this review. The articles between 2016 and 2020 (including March) were identified by scan- Accepted 7 May 2020 ning Google Scholar, Pub Med, and Science Direct databases. Thirty-five articles were defined from Published online 18 May 188 articles. Three cross-sectional, and 1 prospective cohort design studies in adults, and 3 cross-sec- 2020 tional studies in children were found. Three randomised-control group designed studies which exam- KEYWORDS ined the effect of acute exercise on serum asprosin levels in obese individuals. Asprosin may be a new Appetite; asprosin; exercise; therapeutic biomarker to be considered in the development, but long-term and deep-rooted obesity; systematic review researches are needed, and increasing the number of studies examining the effect of exercise on asprosin in the future might help us to identify the mechanisms underlying the decrease or increase in asprosin after exercise. Introduction obesity, it is necessary to understand especially how appe- tite/nutritional behaviours are regulated in the control of Obesity is a global public health problem, and ranked 5th body weight, and this also helps to develop new strategies with 4.8% of deaths worldwide (Wilson et al.
    [Show full text]
  • INFLAMMATION-DERIVED GROWTH FACTORS Optic Nerve Regeneration Is Becoming a Reality
    INFLAMMATION-DERIVED GROWTH FACTORS Optic nerve regeneration is becoming a reality. BY YUQIN YIN, MD, PHD; AND LARRY I. BENOWITZ, PHD ptic nerve trauma, ischemia, and or RAGs) in a pattern similar to that seen mannose, which is abundant in the vit- certain degenerative eye diseases during peripheral nerve regeneration.3 reous and cerebrospinal fluid, stimulates can lead to permanent vision Genetic deletion of two receptors appreciable axon growth from goldfish Oloss due to the inability of retinal that are expressed by inflammatory cells, RGCs and moderate outgrowth from rat ganglion cells (RGCs) to regenerate the Toll-like receptor 2 (TLR2) and dectin-1, RGCs. These effects require elevation of axons that convey visual information eliminates the proregenerative effects of cAMP and are strongly augmented by from the eye to the brain and the sub- zymosan, despite not altering the general a protein secreted by activated macro- sequent death of RGCs. Over the past profile of infiltrative cells.4 β-glucan is a phages.2,8 Using column chromatogra- 20 years, considerable progress has been component of zymosan that stimulates phy, mass spectrometry, and bioassays, made in defining factors that promote cells of the innate immune system via we identified the 11 kDa Ca2+-binding or suppress axon regeneration and RGC dectin-1, and curdlan, a particulate form protein oncomodulin (Ocm) as a major survival after optic nerve injury. of β-glucan, mimics the effects of zymo- growth-promoting factor associated This article describes research from san on regeneration.4 with inflammation.9 our lab that has identified trophic fac- Combining intraocular inflammation Ocm is secreted by infiltrative neutro- tors derived from inflammatory cells with elevation of cAMP and PTEN dele- phils and macrophages, and it accumu- that promote appreciable levels of tion in RGCs and other cells infected lates in the neural retina 12 to 24 hours optic nerve regeneration.
    [Show full text]